Table 2.
Reported antibacterial administration method
| Usual method of administration per CCU, n (%) | |||||||
|---|---|---|---|---|---|---|---|
| B | S/B | S/SPC | EII | CI | N/A | No. of CCUs | |
| Benzylpenicillin | 30 (48.4) | 6 (9.7) | 22 (35.5) | 4 (6.4) | 2 | 62 | |
| Flucloxacillin | 30 46.9) | 8 (12.5) | 22 (34.4) | 4 (6.2) | 64 | ||
| Amoxicillin | 38 (65.5) | 8 (13.8) | 12 (20.7) | 6 | 58 | ||
| Ampicillin | 1 (50) | 1 (50) | 62 | 2 | |||
| Co-amoxiclav | 40 (67.8) | 13 (22) | 6 (10.2) | 5 | 59 | ||
| Piperacillin/tazobactam | 17 (27) | 32 (50.8) | 14 (22.2) | 1 | 63 | ||
| Ticarcillin/clavulanic acid | 10 (100) | 54 | 10 | ||||
| Cefotaxime | 20 (60.6) | 2 (6.1) | 11 (33.3) | 31 | 33 | ||
| Ceftazidime | 20 (40.8) | 1 (2) | 20 (40.8) | 8 (16.4) | 15 | 49 | |
| Ceftriaxone | 22 (36.7) | 1 (1.7) | 33 (55) | 4 (6.6) | 4 | 60 | |
| Cefuroxime | 24 (61.5) | 11 (28.2) | 4 (10.3) | 25 | 39 | ||
| Doripenem | 2 (66.7) | 1 (33.3) | 61 | 3 | |||
| Ertapenem | 5 (13.2) | 33 (86.8) | 26 | 38 | |||
| Imipenem/cilastatin | 5 (100) | 59 | 5 | ||||
| Meropenem | 29 (45.3) | 4 (6.3) | 18 (28.1) | 13 (20.3) | 64 | ||
| Tigecycline | 38 (100) | 26 | 38 | ||||
| Clarithromycin | 63 (98.4) | 1 (1.6) | 64 | ||||
| Clindamycin | 62 (96.8) | 2 (3.2) | 64 | ||||
| Vancomycin | 32 (50.8) | 31 (49.2) | 1 | 63 | |||
| Teicoplanin | 34 (57.6) | 25 (42.4) | 5 | 59 | |||
| Linezolid | 60 (96.7) | 2 (1.7) | 2 | 62 | |||
| Ciprofloxacin | 64 (100) | 64 | |||||
B, bolus injection, i.e. over 5 min or less; S/B, short infusion as per the SPC or bolus injection (dependent on dose); S/SPC, short infusion as per the SPC; EII, extended intermittent infusion, i.e. the drug is infused over a period that is longer than that suggested in the SPC; CI, Continuous infusion, i.e. the drug is infused continuously for the duration of the treatment course; N/A, agent not used